Dr. Reddy's Laboratories CEO Erez Israeli speaks to Street Signs, CNBC, on Q2 FY'24

Our record sales and profitability in Q2 FY’24 was driven by our core generics business. In our innovative products business, we are building a diverse portfolio in India. In the recent past, we have signed deals with Jiangsu Hengrui & Junshi Lifesciences respectively to bring novel molecules such as pyrotinib to India and toripalimab to India and Emerging Markets. We have received approval from the DCGI to proceed with the clinical trial of our CAR-T asset. We have taken initial steps in digital therapeutics, and also e-commerce through our platform 'Celevida Wellness' in India. We will continue to explore inorganic opportunities in India and Emerging Markets that complement our existing strengths and interests.

In this #WeekendWatch, watch this interview excerpt of our CEO, Erez Israeli. Video courtesy of  ‪@CNBC‬ YouTube Channel. All copyrights belong to  ‪@CNBC‬.